883195-08-2

Usage

Uses

Used in Pharmaceutical Industry:
Cyclohexanamine, 4-(4-methyl-1-piperazinyl)-, transis used as a medication for treating various mental disorders such as depression and anxiety. It functions as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the brain by blocking its reabsorption by neurons, thereby improving mood, reducing anxiety, and alleviating other symptoms of mental illness.
Used in Neurotransmitter Research:
As a potential ligand for various neurotransmitter receptors, Cyclohexanamine, 4-(4-methyl-1-piperazinyl)-, transis utilized in research and development for its therapeutic potential in modulating neurotransmission and exploring novel treatment options for neurological and psychiatric conditions.

Upstream product

• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 1119283-62-3 (trans)-N,N-dibenzyl-4-(4-methylpiperazin-1-yl)cyclohexanamine 
• 109-01-3 1-methyl-piperazine 
• 27514-08-5 N-(4-oxocyclohexyl)acetamide 

Downstream Products

• 1280665-07-7 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-N-[(trans)-4-(4-methylpiperazin-1-yl)cyclohexyl]-2,3-dihydrobenzofuran-4-carboxamide 
• 1280665-04-4 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,2-dimethyl-N-[(trans)-4-(4-methylpiperazin-1-yl)cyclohexyl]-3H-benzofuran-4-carboxamide 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE

In one aspect, the invention relates to a process for preparing a compound of formula (XII), wherein PG is a protecting group, or a compound of formula (XI), comprising the steps of: (i) treating a compound of formula XIII, wherein PG is a protecting group, with N- methylpiperazine to form a compound of formula XII, wherein said compound of formula XII is in the form of a mixture of cis and trans isomers; (ii) combining the mixture formed in step (i) with an organic solvent and heating the solvent mixture so formed; (iii) isolating the trans-isomer of the compound of formula XII from the solvent mixture formed in step (ii); and (iv) optionally treating said trans-isomer of the compound of formula XII with an acid to form a compound of formula XI; and isolating said compound of formula XI. Further aspects of the invention relate to processes for preparing pyrimido-diazepinone derivatives using the above process and intermediates.

CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE

The present invention relates to new crystalline forms of a pyrimido-diazepine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

NEW COMPOUNDS

Novel compounds of which the following is exemplary: